Medical Gas Market Size to Hit USD 36.92 Billion by 2035 | SNS Insider

The medical gas market is projected to grow, with North America holding over 37% of 2025 revenue and the U.S. forecast to reach $9.20B by 2035. Europe is expected to rise from $5.76B to $13.32B at an 8.83% CAGR, supported by increasing demand for oxygen therapy, hospital infrastructure, and home healthcare.

Analysis

The investable implication is less about a headline growth rate and more about a sticky, regulated recurring-revenue niche with very limited customer churn. That favors scaled industrial gas franchises with healthcare distribution density and pricing discipline, while smaller regional suppliers are more exposed to delivery economics, cylinder logistics, and hospital tender pressure. The second-order winner is the home-care ecosystem: as oxygen therapy shifts outside hospitals, the profit pool likely moves from pure gas volume toward installed equipment, service contracts, and monitoring — not every dollar of market growth accrues to gas producers.

The market may be underestimating how defensive this theme is across the cycle: utilization is driven by aging demographics and care setting migration, so the 6-18 month path is steadier than most healthcare-adjacent industrials. The main near-term risk is reimbursement or procurement compression, especially in Europe where growth can be offset by price controls and fragmented tendering. If home concentrator adoption accelerates faster than expected, reported market growth could outpace actual consumable gas demand, which would cap upside for suppliers.

This is not a catalyst-rich trade for the next few days; the better horizon is 1-3 quarters for budget and contract renewals, and 6-18 months for structural mix shift. Consensus is probably too focused on volume growth and not enough on margin mix and switching costs. The thesis is falsified if medical gas pricing rolls over, hospital capex slows materially, or reimbursement changes push care back into lower-growth channels.

Key Decisions for Investors

• Use pullbacks to build a medium-term long in LIN as the cleanest public proxy for healthcare gas/service mix; target 6-12 months, with the thesis invalidated by a clear deceleration in healthcare-led segment growth or weaker pricing discipline.
• If we need a relative-value expression, go long LIN / short a basket of more cyclical industrials (XLI) for 3-6 months: the spread should favor a defensive recurring-revenue name if healthcare demand stays stable.
• Avoid chasing smaller regional gas suppliers until we see evidence of margin resilience; their logistics and tender exposure make them more vulnerable if procurement turns price-driven over the next 1-3 quarters.
• Watch for European reimbursement/tender updates as the key catalyst set; if pricing pressure emerges, reduce exposure quickly because the market may be pricing the top line but not the margin compression.